Spyryx Biosciences Overview

  • Founded
  • 2013
  • Status
  • Out of Business
  • Employees
  • 10
  • Latest Deal Type
  • Out of Business

Spyryx Biosciences General Information


Operator of a privately held, clinical-stage biopharmaceutical company intended to create innovative therapeutics to address severe lung diseases. The company's therapeutics utilizes inhaled peptides to treat severe pulmonary diseases where mucus accumulation and obstructions are key to disease progression, enabling healthcare institutes to get peptide for the treatment of orphan lung and respiratory diseases like Cystic Fibrosis and Chronic Obstructive Pulmonary Disorder.

Contact Information

Formerly Known As
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 801-10 Capitola Drive
  • Durham, NC 27713
  • United States
+1 (919) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Spyryx Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Sep-2019 000.00 Completed Out of Business
3. Later Stage VC 04-Oct-2018 000.00 000.00 Completed Clinical Trials - Phase 2
2. Grant 20-Jun-2017 $5M $18.2M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 24-Apr-2015 $18.2M $18.2M 000.00 Completed Product Development
To view Spyryx Biosciences’s complete valuation and funding history, request access »

Spyryx Biosciences Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Spyryx Biosciences’s complete cap table history, request access »

Spyryx Biosciences Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Operator of a privately held, clinical-stage biopharmaceutical company intended to create innovative therapeutics to add
Durham, NC
10 As of 2017
00000000 00 000.00


minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Dui
0000 000000000
Southampton, United Kingdom
00 As of 0000
000000000 00000

0000 000

lum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
0000 000000000
Austin, TX
00 As of 0000
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spyryx Biosciences Competitors (12)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synairgen Corporation Southampton, United Kingdom 00 00000 000000000 00000
0000 000000000000 Venture Capital-Backed Austin, TX 00 000.00 0000000000 000.00
0000000000 0000000 Corporation San Francisco, CA 000 000000&0
000000 Angel-Backed Albuquerque, NM 0 00000 0000000000 00000
0000000000 0000000 Venture Capital-Backed Brighton, United Kingdom 00 000.00 0000000000 0 000.00
You’re viewing 5 of 12 competitors. Get the full list »

Spyryx Biosciences Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial